Quetmolimab clinical trials
Also written E6011.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses quetmolimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- E6011
- 8
Studies by the year they started
9 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Eisai Co., Ltd. (5) · EA Pharma Co., Ltd. (3) · Eisai Inc. (1)
Studies
Open first, then newest update. How each study uses quetmolimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study of E6011 in Participants With Active Crohn's DiseaseCompletedPhase 2EA Pharma Co., Ltd.NCT03733314Written as E6011
- A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's DiseaseCompletedPhase 1/2EA Pharma Co., Ltd.NCT02039063Written as E6011 2 mg/kg
- A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to BiologicsCompletedPhase 2Eisai Co., Ltd.NCT02960490Written as E6011
- A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to MethotrexateCompletedPhase 2Eisai Co., Ltd.NCT02960438Written as E6011
- A Study of E6011 in Japanese Subjects With Rheumatoid ArthritisCompletedPhase 1/2Eisai Co., Ltd.NCT02196558Written as E6011
- Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic AcidTerminatedPhase 2EA Pharma Co., Ltd.NCT03092765Written as E6011
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's DiseaseWithdrawnPhase 1Eisai Inc.NCT02249078Written as E6011
- A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male SubjectsCompletedPhase 1Eisai Co., Ltd.NCT02146261Written as E6011
- A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)CompletedPhase 1Eisai Co., Ltd.NCT01731275Written as E6011
Codes
What other systems call quetmolimab · ClinicalTrials.gg INT000951
- MeSH (NLM) C000627635quetmolimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) G8NT4Q571BQUETMOLIMABConfirmed FDA, NLM
- NCI Thesaurus C170361QuetmolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627635 | quetmolimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | G8NT4Q571B | QUETMOLIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C170361 | Quetmolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.